WHO Collaborating Centre for International Drug
Monitoring. The importance of pharmacovigilance.
Geneva: WHO;
2002. Available: www.who.int/medicines/library/qsm/ip_booklet.pdf
(accessed October 20, 2004).
2.
FitzGeraldGAPatronoC. The coxibs, selective inhibitors of
cyclooxygenase-2. N Engl J Med2001;345(6):433–42.
3.
FitzGeraldGA. COX-2 and beyond: approaches to prostaglandin
inhibition in human disease. [Review]. Nature Reviews Drug
Discovery2003;2(11):879–90.
4.
BombardierCLaineLReicinAShapiroDBurgos-VargasRDavisB, et alComparison of upper gastrointestinal toxicity of rofecoxib and
naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med2000;343(21):1520–8.
5.
TopolEJ. Failing the public health — rofecoxib, Merck, and the
FDA. N Engl J Med2004;351:1707–9.
6.
MamdaniMRochonPAJuurlinkDNKoppAAndersonGMNaglieG, et alObservational study of upper gastrointestinal haemorrhage in elderly
patients given selective cyclo-oxygenase-2 inhibitors or conventional
non-steroidal anti-inflammatory drugs. BMJ2002;325(7365):624.
7.
LaupacisAPatersonJMMamdaniMRostomAAndersonGM. Gaps in the evaluation and monitoring of new
pharmaceuticals: proposal for a different approach.
CMAJ2003;169(11):1167–70.
8.
McAlisterFALaupacisAWellsGASackettDLfor the Evidence-Based Medicine Working GroupUsers' guides to the medical literature: XIX. Applying clinical trial
results. B. Guidelines for determining whether a drug is exerting (more than) a
class effect. JAMA1999;282(14):1371–7.
9.
MamdaniMJuurlinkDNKoppANaglieGAustinPCLaupacisA. Gastrointestinal bleeding after the introduction of
COX 2 inhibitors: ecological study. BMJ2004;328(7453):1415–6.
